Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02894554
Other study ID # 201310070MINA
Secondary ID
Status Terminated
Phase Phase 4
First received July 7, 2015
Last updated September 5, 2016
Start date July 2014
Est. completion date July 2015

Study information

Verified date September 2016
Source National Taiwan University Hospital
Contact n/a
Is FDA regulated No
Health authority Taiwan: Ministry of Health and Welfare
Study type Interventional

Clinical Trial Summary

The hepatitis B virus (HBV) infection rate among renal transplant recipients was reported from 3% to 20.9%. And patient survival and graft survival rates following renal transplantation may be worsen in HBsAg-positive carriers than in HBsAg-negative recipients. Due to viral replication in asymptomatic HBV carriers induced by post-transplant immunosuppression, liver-related complications, such as liver failure and bleeding, account for 37% to 57% of the mortality cases in HBsAg-positive renal allograft recipients.

Since the late 1990s, Lamivudine has been recognized as an effective and well-tolerated antiviral drug for chronic HBV infection. Lamivudine treatment among HBsAg-positive renal allograft recipients has significantly improved patient survival rates during short-term follow-up. Telbivudine is another approved nucleoside antiviral agent for patients with chronic hepatitis B (CHB). Recently, it was shown that eGFR was improved in HBV-related decompensated cirrhosis patients after 52 weeks Telbivudine treatments. Additional eGFR increase was also observed in Lamivudine experienced CHB patients after switch to Telbivudine treatment.

However, limited results were known about the renal function affected by oral anti-HBV drugs when patients received kidney transplantation. Therefore, we would like to conduct this study to evaluate the renal function of Lamivudine long term used HBsAg positive patients received kidney transplantation after switch to Telbivudine treatment. The clinical and virological outcomes will provide valuable insights of clinical practice.


Recruitment information / eligibility

Status Terminated
Enrollment 19
Est. completion date July 2015
Est. primary completion date October 2014
Accepts healthy volunteers No
Gender Both
Age group 20 Years and older
Eligibility Inclusion Criteria:

1. Kidney transplant patients who are treated with Lamivudine over 6 months (Considering include post kidney transplantation > 6 months with stable calcineurin inhibitors level

2. Seropositive of HBsAg for 6 months

3. Willing and able to provide written informed consent

Exclusion Criteria:

1. Hepatitis cirrhosis patients

2. Co-infection with hepatitis C virus or HIV

3. Pregnant or nursing

4. YMDD resistant at baseline

5. ABO incompatible renal transplantation

6. Cross match positive

7. Poor renal function at baseline (eGFR<20)

8. Known hypersensitivity or intolerance to any of the ingredients in Telbivudine

9. Known history of Telbivudine resistance

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms

  • HBsAg-positive Renal Allograft Recipients

Intervention

Drug:
Telbivudine

Lamivudine


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
National Taiwan University Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary To evaluate the renal function in HBsAg positive kidney transplant patients in Telbivudine and Lamivudine treatment groups by eGFR at 48 Weeks after treatment using MDRD formula. 48 weeks No